A Randomized Controlled Trial of Oral Ivermectin for Patients With Chikungunya Viral Infection During Urban Outbreak in Southern Thailand
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Day of fever clearance
研究概览
简要总结
Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •patients with virologic confirmation of chikungunya infection who had symptoms less than 72 hours prior to visit
排除标准
- •patients with virologic confirmation of chikungunya infection who had symptoms more than 72 hours prior to visit
研究组 & 干预措施
Patients received oral ivermectin, adjunctive to conventional treatment
干预措施: Ivermectin (Drug)
结局指标
主要结局
Day of fever clearance
时间窗: 1 week
120 participants would be under Body Temperature Assessment - the staff would assess once daily until the fever clearance was below 38C and the measure proportion of patients with fever clearance in each day of assessment until fever clearance at least in 7 days
次要结局
- Day of virologic clearance(1 week)
研究者
Sarunyou Chusri
Principal Investigator
Prince of Songkla University